TrialsgrambetaRCTs are beautiful

ENGAGE AF-TIMI 48

2013

Effective Anticoagulation with Factor Xa Next Generation in AF

In 21,105 patients with AF at moderate-to-high stroke risk, edoxaban was non-inferior to warfarin for stroke or systemic embolism, with less bleeding.

Result

Primary endpoint: Stroke or systemic embolism

Higher-dose edoxaban non-inferior; major bleed 2.75 %/yr vs 3.43 %/yr; intracranial bleeding roughly halved.

Original publication
Subtopic
Anticoagulation
Design
Double-blind, double-dummy RCT
Relevance
Important: one of several pillars.
Source
Giugliano RP, et al. N Engl J Med. 2013;369(22):2093-2104.doi 10.1056/NEJMoa1310907

Discussion & critique

Completed the four-NOAC evidence base. Reduced efficacy at high creatinine clearance led to a US label restriction, a reminder that NOAC dosing is not one-size-fits-all.

Discussed in podcasts